Avesta76 Therapeutics is excited to welcome impact-focused CANCER FUND, and the community that it it represents, to join our team as an investor. We look forward to an impactful and prosperous partnership in fighting cancer together.
CANCER FUND is pleased to announce its investment in Avesta76 Therapeutics, a cancer therapeutics company developing a novel platform for multiple cancers. The investment represents CANCER FUND’s fifth investment out of Cancer Fund I. It becomes its fourth portfolio company in pursuit of its mission to support cancer innovators advance from the lab to patient care. “We are thrilled to support Avesta76 and add them to our investment portfolio. Early indications show their focused therapeutics offer promise for multiple cancers of interest to our investor community, including chemo-resistant ovarian, breast, and colorectal cancers among others," said CANCER FUND Managing Director Anthony Bajoras. "We believe it may offer a new therapeutic alternative for patients who have developed chemo-resistance to current treatments, saving lives and improving patientsurvival.” "Avesta76 is excited to add Cancer Fund I as an investor and long-term partner. We’ve built a strong relationship with the CANCER FUND team and value both their mission of supporting innovative oncology-focused companies on the path to reach patients and their unique community-driven investment model,” said Avesta76 Therapeutics Co-Founder & CEO Ian Akash Morrison. Learn more: https://lnkd.in/gX5kZTev